We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+31.31%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.59B
AUM Growth
+$94.3M
Cap. Flow
-$331M
Cap. Flow %
-12.8%
Top 10 Hldgs %
60.43%
Holding
115
New
13
Increased
19
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$58.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
3
PYPL icon
PayPal
PYPL
+$20.8M
4
ARGX icon
argenx
ARGX
+$20.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$12.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$70M
2
NVDA icon
NVIDIA
NVDA
+$34.8M
3
AVTR icon
Avantor
AVTR
+$19.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$17M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.99%
2 Consumer Discretionary 25.71%
3 Communication Services 1.46%
4 Technology 1.19%
5 Financials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
Replimune Group
REPL
$438M
$8.61M 0.33%
600,000
– –
ACIU icon
52
AC Immune
ACIU
$231M
$8.52M 0.33%
1,000,000
– –
BMRN icon
53
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$8.46M 0.33%
+100,000
New +$7.55M
RNAC icon
54
Cartesian Therapeutics
RNAC
$223M
$8.12M 0.31%
113,788
+43,788
+63% +$2.11M
BPMC
55
CALL
DELISTED
Blueprint Medicines
BPMC
$8.01M 0.31%
+100,000
New +$7.49M
SLDB icon
56
Solid Biosciences
SLDB
$796M
$8.01M 0.31%
120,000
+6,667
+6% +$736K
CLVS
57
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$7.82M 0.3%
+750,000
New +$5.45M
TGTX icon
58
TG Therapeutics
TGTX
$8.28B
$7.21M 0.28%
650,000
-250,000
-28% -$1.9M
NERV icon
59
Minerva Neurosciences
NERV
$196M
$7.11M 0.27%
125,000
– –
MRUS
60
DELISTED
Merus
MRUS
$7.04M 0.27%
500,000
– –
NIO icon
61
CALL
NIO
NIO
$12B
$7.04M 0.27%
1,750,000
– –
BBIO icon
62
BridgeBio Pharma
BBIO
$16.6B
$7.01M 0.27%
200,000
– –
DNLI icon
63
Denali Therapeutics
DNLI
$3.8B
$6.97M 0.27%
400,000
– –
AUTL
64
Autolus Therapeutics
AUTL
$381M
$6.6M 0.26%
500,000
– –
IMUX icon
65
Immunic
IMUX
$177M
$6.11M 0.24%
+63,002
New +$5.24M
RGNX icon
66
Regenxbio
RGNX
$617M
$5.94M 0.23%
145,000
– –
IGMS
67
DELISTED
IGM Biosciences
IGMS
$5.72M 0.22%
150,000
-50,000
-25% -$1.26M
TCRR
68
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.71M 0.22%
400,000
-71,846
-15% -$1.11M
KURA icon
69
Kura Oncology
KURA
$795M
$5.5M 0.21%
400,000
+150,000
+60% +$2.22M
LGF.A
70
CALL
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
$5.33M 0.21%
500,000
– –
TBIO
71
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.29M 0.2%
650,000
-100,000
-13% -$923K
FOLD
72
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.87M 0.19%
500,000
– –
ORTX
73
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.81M 0.19%
35,000
– –
SPRO icon
74
Spero Therapeutics
SPRO
$68.9M
$4.81M 0.19%
500,000
-40,000
-7% -$431K
PRTA icon
75
Prothena Corp
PRTA
$444M
$4.75M 0.18%
+300,000
New +$3.22M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2019 Portfolio in Review

As of Q4 2019, Artal Group held 115 positions worth $2.59B, up 3.8% from $2.49B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group withdrew a net $331M in Q4 2019, closing 19 positions and reducing 20 holdings. Its most notable exit was Medicines Co, an estimated $70M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Artal Group opened a new position in BioNTech worth $89M.

  • Artal Group's largest Q4 2019 buy was BioNTech: 2,628,130 shares worth $89M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2019, an estimated $29.9M increase.
  • Artal Group's biggest Q4 2019 reduction was Avantor, cutting an estimated $19.9M.
  • Artal Group fully exited Medicines Co in Q4 2019, selling an estimated $70M.
  • Artal Group's ten largest holdings make up 60% of its $2.59B portfolio in Q4 2019.
  • Artal Group opened 13 new positions and closed 19 in Q4 2019.
  • Artal Group's portfolio value rose 3.8% quarter-over-quarter to $2.59B.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.